University of California San Diego Health

UC San Diego Health Joins International Clinical Trial to Test Coronavirus Vaccine

Janssen trial will recruit up to 60,000 participants around the world to assess safety and efficacy of a single-dose vaccine to prevent COVID-19

Newswise — UC San Diego Health will be a test site for a third, major Phase III clinical trial to assess a vaccine candidate for SARS-CoV-2, the novel coronavirus that causes COVID-19.

Sponsored by Janssen Pharmaceuticals Companies of Johnson & Johnson, the trial will recruit up to 60,000 participants at sites in the United States, Brazil, Chile, Colombia, Mexico, Peru, Argentina, Philippines, South Africa and Ukraine to test a single-dose investigational vaccine injection. Dubbed ENSEMBLE, the trial in San Diego officially launches October 7, 2020.

Like the Moderna and AstraZeneca COVID-19 vaccine trials already underway at UC San Diego Health and elsewhere, the Janssen trial will be a randomized, double-blind, placebo-controlled study. It will assess the efficacy, safety and immunogenicity (the ability to provoke an immune response) of the investigational drug Ad.26-COV2.S.

The Janssen trial employs an older, well-tested vaccine development approach: A deactivated common cold virus is modified to carry the SARS-CoV-2’s characteristic spike protein, which the virus uses to enter host cells. This vaccine “vector” is injected, and the presence of the spike protein prompts the human immune system to create neutralizing antibodies to block the targeted pathogen, essentially rendering subsequent exposures to the coronavirus as non-infectious.

“The Janssen vaccine strategy builds upon their extensive experience using the same vaccine platform for many other infectious diseases, including HIV, Ebola and malaria,” said Susan Little, MD, professor of medicine at UC San Diego School of Medicine and principal investigator of the UC San Diego trial. “No significant safety issues have been identified in studies of more than 90,000 people using this same vaccine platform for other infectious diseases.”

In late-July, researchers published online pre-clinical data in the journal Nature showing that a single injection of Ad.26-COV2.S produced a “robust immune response” in rhesus macaques. In other words, it generated levels of neutralizing antibodies that provides near- or complete protection from COVID-19 infections in the lungs of the monkeys.

The early findings were encouraging enough for Janssen to immediately announce the launch a two-year-long Phase I/IIa first-in-human clinical trial in the United States and Belgium. Interim, non-peer-reviewed results of that study, published September 25, 2020 on the preprint site medRxiv, found that safety and immunogencicity supported further clinical development.

Participation Protocol

The Phase III ENSEMBLE trial at UC San Diego Health will recruit an estimated 2,000 participants. Half of the participants will receive a single injection of the Ad.26-COV2.S investigational vaccine and the other half will receive a placebo; all will be regularly monitored for signs of infection and COVID-19 over the next two years. Qualifying participants must be 18 or older and in reasonably good health.

Like the other trials, researchers are especially interested in participants at increased risk of SARS-CoV-2 infection due to where they live (higher community spread of the virus), age or personal circumstances, such as working in essential jobs like first responders, health care, maintenance, construction, grocery stores or assisted living facilities.

There is an emphasis upon participation in underserved communities, particularly those of color, that have shown higher rates of both hospitalization and death due to COVID-19. According to the latest available data from the County of San Diego’s Health and Human Services Agency, the countywide rate of SARS-CoV-2 infection is 1,442 cases per 100,000 population. In the southern half of the county, however, the rate is measurably higher: Chula Vista — 2,207; Imperial Beach — 2,189; National City — 2,598.

To permit easier access to the study in these communities, UC San Diego trial coordinators have contracted with National City to establish a testing location in trailers that will be set up in the parking lot of Toyon Park. The site is scheduled to operate through October 2022. Additional outreach efforts are planned.

“Many communities of color are experiencing higher rates of hospitalization related to COVID-19 than are observed in White, non-Hispanic people,” said Little. “It is important that these communities are represented in COVID-19 vaccine clinical trials so that we understand if the vaccine will work well within these groups.”

The Janssen trial is part of the National Institutes of Health’s (NIH) COVID-19 Prevention Network (CoVPN) and Operation Warp Speed, a program sponsored by the U.S. Department of Health and Human Services, with a goal to deliver 300 million doses of a safe, effective vaccine for COVID-19 by end of year or early 2021. Currently, Operation Warp Speed has now committed a reported $8 billion to development and/or purchase of different vaccines under investigation by AstraZeneca, Moderna, Janssen/Johnson & Johnson, Pfizer/BioNTech SE, NovaVax, Merck and Sanofi/GSK, the last a European-based partnership.

Belgium-based Janssen Pharmaceutica was purchased by the American health conglomerate Johnson & Johnson in 1961. Janssen opened a 122,000-square-foot life sciences facility in San Diego in 2012; Johnson & Johnson has maintained a research center in in the region for more than two decades. Both entities have had long and varied research collaborations with UC San Diego.

For more information about participating in the Janssen trial at UC San Diego, visit www.covidvaccinesd.com or call 619-742-0433.

For information on other COVID-19 clinical trials at UC San Diego, visit clinicaltrials.ucsd.edu/covid-19.

###




Filters close

Showing results

1120 of 5634
Newswise: 264700_web.jpg
Released: 12-May-2021 4:55 PM EDT
COVID-19 vaccine does not damage the placenta in pregnancy
Northwestern University

A new Northwestern Medicine study of placentas from patients who received the COVID-19 vaccine during pregnancy found no evidence of injury, adding to the growing literature that COVID-19 vaccines are safe in pregnancy.

Newswise: For the first time, Argonne researchers reveal how COVID-19 has transformed communities
Released: 12-May-2021 4:05 PM EDT
For the first time, Argonne researchers reveal how COVID-19 has transformed communities
Argonne National Laboratory

Argonne researchers have launched new map-based tools that show how communities held up as COVID-19 spread.

Released: 12-May-2021 3:45 PM EDT
Parks not only safe, but essential during the pandemic
Drexel University

Parks played an important role for people seeking respite from the toll of social isolation during the pandemic, and according to new research from Drexel University, they did so without increasing the spread of COVID-19.

access_time Embargo lifts in 2 days
Embargo will expire: 18-May-2021 11:00 AM EDT Released to reporters: 12-May-2021 3:35 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 18-May-2021 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: Pandemic Has 'Severely Weakened Surgical Innovation Pipeline'
Released: 12-May-2021 3:15 PM EDT
Pandemic Has 'Severely Weakened Surgical Innovation Pipeline'
Johns Hopkins University Carey Business School

In a new study for the journal Surgical Innovation, Associate Professor Toby Gordon of the Johns Hopkins Carey Business School addresses the ways in which COVID-19 has slowed medical innovation.

Released: 12-May-2021 2:55 PM EDT
Mental health helplines need human-centered solutions
Cornell University

In India today, dozens of phone numbers are available for people who are having a severe mental health emergency. Oftentimes, however, callers experience difficulty in getting connected with someone who will listen to them; sometimes the phone will just ring and ring.

Newswise: Weizmann Institute Scientists Reveal the Triple Threat of Coronavirus
Released: 12-May-2021 2:40 PM EDT
Weizmann Institute Scientists Reveal the Triple Threat of Coronavirus
Weizmann Institute of Science

Scientists at the Weizmann Institute and the Israel Institute for Biological, Chemical and Environmental Sciences took a novel tack to investigating SARS-CoV-2’s powerful ability to infect, finding that the virus deploys an apparently unique three-pronged strategy to take over the cell’s protein-synthesis abilities. The work could help develop effective Covid-19 treatments.

Newswise: Rush Collaborates With Malcolm X College to Train COVID-19 Vaccine Ambassadors
Released: 12-May-2021 2:20 PM EDT
Rush Collaborates With Malcolm X College to Train COVID-19 Vaccine Ambassadors
Rush University Medical Center

Rush staff members collaborated with Malcom X College to provide content including video scenarios and conversation advice, for a new Vaccine Ambassador Course offered to the public.

Newswise: Using Ultrasound Stimulation to Reduce Inflammation in COVID-19 In-Patients
Released: 12-May-2021 1:35 PM EDT
Using Ultrasound Stimulation to Reduce Inflammation in COVID-19 In-Patients
University of California San Diego Health

Researchers at UC San Diego School of Medicine have begun a pilot clinical trial to test the efficacy of using ultrasound to stimulate the spleen and reduce COVID-19-related inflammation, decreasing the length of hospital stays.

Released: 12-May-2021 9:00 AM EDT
Rapid COVID-19 Diagnostic Test Delivers Results Within 4 Minutes With 90 Percent Accuracy
Perelman School of Medicine at the University of Pennsylvania

A low-cost, rapid diagnostic test for COVID-19 developed by Penn Medicine provides COVID-19 results within four minutes with 90 percent accuracy. A paper published this week in Matter details the fast and inexpensive diagnostic test, called RAPID 1.0. Compared to existing methods for COVID-19 detection, RAPID is inexpensive and highly scalable, allowing the production of millions of units per week.


Showing results

1120 of 5634

close
33.66542